AREC — Arecor Therapeutics Balance Sheet
0.000.00%
- £14.35m
- £11.32m
- £5.05m
Annual balance sheet for Arecor Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2.9 | 18.3 | 12.8 | 6.75 | 3.26 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.86 | 1.57 | 2.82 | 3.32 | 4.5 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 3.82 | 20.5 | 17.5 | 11.2 | 8.23 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.375 | 0.328 | 0.838 | 0.834 | 0.4 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Total Assets | 4.28 | 20.9 | 21.8 | 15.4 | 8.72 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.41 | 2.27 | 3.73 | 5.15 | 3.26 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.51 | 2.37 | 4.31 | 5.85 | 3.37 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 0.774 | 18.5 | 17.5 | 9.53 | 5.35 |
Total Liabilities & Shareholders' Equity | 4.28 | 20.9 | 21.8 | 15.4 | 8.72 |
Total Common Shares Outstanding |